Early Identification and Management of Patients with Rash on Apalutamide

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Apalutamide, an androgen receptor inhibitor, effectively treats prostate cancer.
• Skin rash is a common side effect of apalutamide, potentially leading to treatment interruption.
• Early management of apalutamide-related rash is vital to prevent treatment discontinuation.

Purpose of the Study:

• To develop practical guidance for managing apalutamide-induced skin rash.
• To emphasize the importance of patient education and early intervention.
• To provide recommendations for rash management based on severity.

Main Methods:

• Development of practical management guidelines for apalutamide-related rash.
• Creation of an infographic detailing rash management by grade.
• Focus on patient education regarding skin care and reporting of adverse events.

Main Results:

• Proactive patient education and early reporting of skin changes are key.
• Timely intervention facilitates quicker rash resolution.
• Effective rash management enables patients to continue apalutamide therapy.

Conclusions:

• Early identification and management of apalutamide-related rash are essential.
• Patient education and vigilance by the care team improve treatment adherence.
• This approach supports continued apalutamide treatment, potentially delaying prostate cancer progression.